Article

Comparison of marker gene expression in chondrocytes from patients receiving autologous chondrocyte transplantation versus osteoarthritis patients.

NMI Natural and Medical Sciences Institute at the University of Tübingen, Markwiesenstrasse, 72770 Reutlingen, Germany.
Arthritis research & therapy (Impact Factor: 4.27). 02/2007; 9(3):R60. DOI: 10.1186/ar2218
Source: PubMed

ABSTRACT Currently, autologous chondrocyte transplantation (ACT) is used to treat traumatic cartilage damage or osteochondrosis dissecans, but not degenerative arthritis. Since substantial refinements in the isolation, expansion and transplantation of chondrocytes have been made in recent years, the treatment of early stage osteoarthritic lesions using ACT might now be feasible. In this study, we determined the gene expression patterns of osteoarthritic (OA) chondrocytes ex vivo after primary culture and subculture and compared these with healthy chondrocytes ex vivo and with articular chondrocytes expanded for treatment of patients by ACT. Gene expression profiles were determined using quantitative RT-PCR for type I, II and X collagen, aggrecan, IL-1beta and activin-like kinase-1. Furthermore, we tested the capability of osteoarthritic chondrocytes to generate hyaline-like cartilage by implanting chondrocyte-seeded collagen scaffolds into immunodeficient (SCID) mice. OA chondrocytes ex vivo showed highly elevated levels of IL-1beta mRNA, but type I and II collagen levels were comparable to those of healthy chondrocytes. After primary culture, IL-1beta levels decreased to baseline levels, while the type II and type I collagen mRNA levels matched those found in chondrocytes used for ACT. OA chondrocytes generated type II collagen and proteoglycan-rich cartilage transplants in SCID mice. We conclude that after expansion under suitable conditions, the cartilage of OA patients contains cells that are not significantly different from those from healthy donors prepared for ACT. OA chondrocytes are also capable of producing a cartilage-like tissue in the in vivo SCID mouse model. Thus, such chondrocytes seem to fulfil the prerequisites for use in ACT treatment.

0 Bookmarks
 · 
48 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Topics: Aufbau und Funktion des hyalinen Knorpels; Prinzip des Regenerationsgewebes; Genese der traumatischen Gelenkdegeneration und Arthrose (OA); Genese der nicht-traumatischen Gelenkdegeneration und Arthrose (OA); Inzidenz von Schäden des hyalinen Knorpels; Bedeutung der OA für den Patienten und das Gesundheitssystem; Welche Gelenke können therapiert werden?; Chirurgische Methoden zur Restauration des hyalinen Knorpels; MACT: Wirkungs-Prinzip und klinische Indikationen; Vergleich MAC mit anderen Verfahren: Evidenzlage; Vergleich MACT und Mikrofrakturierung: Defektgröße; Vergleich MACT und Mikrofrakturierung: Rückkehr zum Sport, klinische Nachhaltigkeit; MACT: Korrelation von Gewebequalität und klinischem Verlauf; MACT: Langfristiger klinischer Erfolg; MACT und OA; MACT: Verbesserungskonzepte; AMIC: Wirkungs-Prinzip; AMIC: klinische Indikationen und Hinweise zur Mikrofrakturierung; AMIC: Klinische Ergebnisse; AMIC: Zusamenfassung; Knorpel-Rekonstruktion: neue Impulse, neue Produkte; Nationale Firmen und Produkte - Amedrix GmbH; Arthro-Kinetics AG; BioTissueTechnologies GmbH; CellGenix GmbH; Co.don AG; TETEC AG; TiGenix N.V.; Internationale Firmen und Produkte - Genzyme Biosurgery/ Sanofi-Aventis; Fidia Advanced Biopolymers; CellMatrix Cartilix; Tissue Bank of France (TBF); Histogenics; DePuy Mitek / Johnson & Johnson Regenerative Therapeutics LLC; ISTO Technologies, Inc. / Zimmer, Inc.; Zukünftige Therapiekonzepte: Identifizierung und Modulation geeigneter Stoffwechselwege; Zukünftige Therapiekonzepte: Transplantation adulter mesenchymaler Stammzellen; Fazit
    01/2013: pages 35-47; , ISBN: ISBN 978-3609769912
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: Minced chondral fragments are becoming popular as a source of cells for cartilage repair, as a growing interest is developing towards one-stage procedures to treat cartilage lesions. The purpose of this study is to (A) compare cell outgrowth from cartilage fragments of adult and young donors using two different types of scaffolds and (B) evaluate the influence of transforming-growth-factor-β1 (TGF-β1) and granulocyte colony-stimulating factor (G-CSF) on chondrocyte behaviour. METHODS: In part (A) cartilage fragments from adult and young donors were either loaded onto an HA-derivative injectable paste scaffold or onto an HA-derivative membrane scaffold. Construct sections were then examined for cell counting after 1, 2 and 3 months. In part (B) only membrane scaffolds were prepared using cartilage fragments from young donors. Constructs were cultured either in standard growth medium or in the presence of specific growth factors, such as TGF-β1 or G-CSF or TGF-β1 + G-CSF. After 1 month, construct sections were examined for cell counting. Expression of chondrocyte markers (SOX9, CD151, CD49c) and proliferative markers (β-catenin, PCNA) was assessed using immunofluorescence techniques, both in unstimulated construct sections and in cells from unstimulated and stimulated construct cultures. RESULTS: Part (A): histological analysis showed age-dependent and time-dependent chondrocyte migration. A significant difference (p < 0.05) was observed between young and older donors at the same time point. No difference was detected between the two types of scaffolds within the same group at the same time point. Part (B): after 1 month, the number of migrating cells/area significantly increased due to exposure to TGF-β1 and/or G-CSF (p < 0.05). Immunofluorescence revealed that outgrowing cells from unstimulated scaffold sections were positive for SOX9, CD151, CD49c and G-CSF receptor. Immunofluorescence of cells from construct cultures showed an increase in β-catenin in all stimulated groups and an increased PCNA expression in G-CSF-exposed cultures (p < 0.05). CONCLUSION: Outgrowing cells may represent a subset of chondrocytes undergoing a phenotypic shift towards a proliferative state. TGF-β1, and to a greater extent G-CSF, may accelerate this outgrowth. The clinical relevance of this study may involve a potential future clinical application of scaffolds preloaded with growth factors as an additional coating for chondral fragments. Indeed, a controlled delivery of G-CSF, widely employed in various clinical settings, might improve the repair process driven by minced human cartilage fragments during one-stage cartilage repair.
    Knee Surgery Sports Traumatology Arthroscopy 11/2012; · 2.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we investigated genetic damage acquisition during in vitro culture of human osteoarthritic (OA) chondrocytes to evaluate their safety for use in regenerative medicine clinical applications. In particular, we have addressed the impact of long-term in vitro culture on simple sequence repeat stability, to evaluate the involvement of the mismatch repair system (MMR) in the accumulation of genetic damage. MMR, the main post-replicative correction pathway, has a fundamental role in maintaining genomic stability and can be monitored by assessing microsatellite instability (MSI). MMR activity has been reported to decrease with age not only in vivo, but also in vitro in relationship to culture passages. OA chondrocytes from seven donors were cultured corresponding to 13-29 population doublings. Aliquots of the cells were collected and analyzed for MSI at five DNA loci (CD4, VWA, FES, TPOX, and P53) and for MMR gene expression at each subculture. Genetic stability was confirmed throughout the culture period. MMR genes demonstrated a strong coordination at the transcriptional level among the different components; expression levels were very low, in accordance with the observed genetic stability. The reduced expression of MMR genes might underline no need for increasing DNA repair control in the culture conditions tested, in which no genetic damage was evidenced. These data argue for the safety of chondrocytes for cellular therapies and are encouraging for the potential use of in vitro expanded OA chondrocytes, supporting the extension of autologous cell therapy procedures to degenerative articular diseases.
    Journal of Cellular Physiology 10/2011; 226(10):2579-85. · 4.22 Impact Factor

Full-text (2 Sources)

View
2 Downloads
Available from
Jun 6, 2014